Key facts
- This page summarizes John M. Siebert's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2023, 16:01.
John M. Siebert - 23 Feb 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Form type
- 4
- Accepted by SEC
- 27 Feb 2023, 16:01:09 UTC
- Previous filing
- 24 Feb 2023
- Next filing
- 26 Feb 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
John M. Siebert filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 27 Feb 2023.
Change
- Previous filing in this sequence was filed on 24 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 84,057
- Date
- 23 Feb 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,293
- Change %
- Price
- $0.000000
- Shares after
- 6,293
- Date
- 23 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,293
- Exercise price
- $38.60
- Footnotes
- F1
SUPN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +3,886
- Change %
- Price
- $0.000000
- Shares after
- 3,886
- Date
- 23 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,886
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vests on February 23, 2024.
Footnote F2
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
Footnote F3
These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024.